Global Community

A little-known builder in Sarawak focuses on government-backed schools and public facilities, which can be steadier work than private property projects. A recent weak quarter spooks the market, but the company is pushing to expand into Peninsular Malaysia—an important test of whether it can scale beyond its home turf.Read more

Walmart’s SBU ‘Other’: A Forward-Looking Perspective As Walmart continues to diversify its business, the SBU “Other” has emerged as a dynamic growth engine, capturing new opportunities beyond traditional retail. The week of June 13–19, 2026, offers a compelling snapshot of this segment’s momentum and sets the stage for future projections.Read more

DISCLAIMER: This is solely for educational purposes, do not take this as investment advice. EQUITY RESEARCH VivoPower PLC Sovereign AI data infrastructure Price (24 Jun 2026) ~$5.68 Market Cap ~$82–92M 52-Week Range A.E. $1.20 – $8.55 Public Float ~3.8M shares Short Interest ~71.7% of float Beta ~2.6 (high) Analyst Consensus Hold (17 analysts) 12M Target Range $6.29 – $13.64 RATING: SPECULATIVE BUY 1.Read more

FY3/26 results update Forging ahead towards the next phase – FY3/26 results were resilient and ahead of the Company’s guidance revised in February 2026. Although macro uncertainty driven by Middle East tensions contributed to a conservative FY3/27 guidance, we think investors should look past the temporary headwind and focus on the Company’s new FY3/27–FY3/31 medium-term plan.Read more

As a quantitative fundamental value investor, I seek out for deep value stocks, estimate their fair value, compute their intrinsic price and run them through my check list to see if I can invest in them. I take the three filter approach for this - is my thesis Possible?Read more

Virtuix starts as a device that lets people walk and run inside virtual worlds, but the bigger story is its push into military training and realistic digital “terrain” made from ordinary video. With major military groups already testing it and a new path to reach a much larger VR headset audience, the company’s next moves could reshape where its growth really comes from.Read more

The market’s current appraisal of Rocket Pharma (RCKT) fails to adequately account for the operational and technical maturity the company has already achieved. While equity markets are quick to assign premiums to emerging technologies, they are often sluggish in recognizing the complex manufacturing infrastructures that characterize true commercial scaling.Read more

The market writes NuScale off after a big project gets canceled, but the bigger story is the growing need for always-on clean power as AI data centers expand. With a reactor design already cleared by U.S. regulators and a model built around factory-made, modular builds, it may be better positioned than the headlines suggest.Read more

Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.Read more